Tandem Diabetes Care (TNDM) Stock Forecast & Price Target

$42.40

-0.36 (-0.84%)

(As of 09/6/2024 ET)

Tandem Diabetes Care - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 16 Analyst Ratings

Based on 16 Wall Street analysts who have issued ratings for Tandem Diabetes Care in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 3 have given a hold rating, and 13 have given a buy rating for TNDM.

Consensus Price Target

$54.36
28.20% Upside

High Forecast	$75.00
Average Forecast	$54.36
Low Forecast	$39.00

According to the 16 analysts' twelve-month price targets for Tandem Diabetes Care, the average price target is $54.36. The highest price target for TNDM is $75.00, while the lowest price target for TNDM is $39.00. The average price target represents a forecasted upside of 28.20% from the current price of $42.40.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	13 Buy rating(s)	11 Buy rating(s)	5 Buy rating(s)
Hold	3 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$54.36	$55.08	$50.58	$46.80
Forecasted Upside	28.20% Upside	30.85% Upside	25.39% Upside	27.14% Upside

Get Tandem Diabetes Care Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.

Ad Golden Crest

Biden's Successor: The Radical Threat to YOUR Savings!

Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.

>> Get Your FREE Wealth Protection Guide <<

TNDM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TNDM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Tandem Diabetes Care Stock vs. The Competition

Type	Tandem Diabetes Care	Medical Companies	S&P 500
Consensus Rating Score	2.81	2.77	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	28.20% Upside	1,207.57% Upside	11.36% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/22/2024	Morgan Stanley 3 of 5 stars		Initiated Coverage	Equal Weight	$45.00	+5.29%
8/8/2024	Canaccord Genuity Group 1 of 5 stars		Initiated Coverage	Buy	$57.00	+53.89%
8/5/2024	Barclays 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$55.00 ➝ $58.00	+42.19%
8/2/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Antalffy Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/2/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$50.00 ➝ $55.00	+31.86%
8/2/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$36.00 ➝ $39.00	-7.16%
Get the Latest News and Ratings for TNDM and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.
8/2/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $55.00	+29.35%
6/10/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$47.00 ➝ $58.00	+18.73%
5/30/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$60.00	+15.94%
5/22/2024	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$60.00 ➝ $75.00	+47.17%
5/22/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$45.00 ➝ $55.00	+11.52%
5/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$40.00 ➝ $57.00	+15.57%
4/25/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
4/25/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$34.00 ➝ $45.00	+28.13%
10/2/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$47.00 ➝ $45.00	+116.66%
8/4/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$52.00 ➝ $34.00	+2.87%
6/13/2023	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$74.00 ➝ $50.00	+93.12%
5/5/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$45.00 ➝ $33.00	-12.02%
4/24/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
2/23/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$61.00 ➝ $52.00	+29.84%
1/26/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Peer Perform
11/3/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$107.00 ➝ $61.00	+64.15%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:14 PM ET.

TNDM Forecast - Frequently Asked Questions

What is Tandem Diabetes Care's forecast for 2024?: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Tandem Diabetes Care is $54.36, with a high forecast of $75.00 and a low forecast of $39.00.
Should I buy or sell Tandem Diabetes Care stock right now?: 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TNDM shares.
Does Tandem Diabetes Care's stock price have much upside?: According to analysts, Tandem Diabetes Care's stock has a predicted upside of 29.00% based on their 12-month stock forecasts.
Has Tandem Diabetes Care been upgraded by Wall Street analysts recently?: Over the previous 90 days, Tandem Diabetes Care's stock had 1 upgrade by analysts.
What analysts cover Tandem Diabetes Care?: Tandem Diabetes Care has been rated by research analysts at Barclays, Canaccord Genuity Group, Canaccord Genuity Group, Morgan Stanley, Oppenheimer, Piper Sandler, Robert W. Baird, UBS Group, and Wells Fargo & Company in the past 90 days.
Do Wall Street analysts like Tandem Diabetes Care more than its competitors?: Analysts like Tandem Diabetes Care more than other "medical" companies. The consensus rating score for Tandem Diabetes Care is 2.81 while the average consensus rating score for "medical" companies is 2.77. Learn more on how TNDM compares to other companies.